Spruce Biosciences, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Spruce Biosciences, Inc. (SPRB) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-04-15
- Spruce Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was -$36.00K.
- Spruce Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Spruce Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $11.00K, a 99.22% decline from fiscal 2022.
- Spruce Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $1.42M.
- Spruce Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-04-15 | ||
| 2023-12-31 | $11.00K 10-K · filed 2025-04-15 | ||
| 2022-12-31 | $1.42M 10-K · filed 2024-03-18 | ||
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 | ||
| 2020-12-31 | -$36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.86M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $1.89M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |